{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-tmf-destruction-and-disposition-documentation”
},
“headline”: “SOP for TMF Destruction and Disposition Documentation”,
“description”: “This SOP defines standardized processes for the destruction and disposition of Trial Master Files (TMF/eTMF) after retention periods, in compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements. It includes chain of custody, destruction certification, witness procedures, and secure shredding/erasure of documents.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for TMF Destruction and Disposition Documentation

Purpose

The purpose of this SOP is to establish a compliant process for destruction and disposition of Trial Master Files (TMF/eTMF) after the retention period defined by applicable regulations. It ensures that documents are destroyed securely, documented properly, and traceability is maintained, while respecting confidentiality and data protection laws.

Scope

This SOP applies to sponsors, CROs, TMF administrators, QA, IT, and qualified destruction vendors involved in the destruction of paper and electronic TMF/eTMF records. It covers chain of custody, vendor oversight, regulatory notifications (where required), destruction certification, and disposition record keeping.

Responsibilities

• Sponsor: Approves TMF destruction plan and ensures compliance with regulatory timelines.
• TMF Administrator: Prepares TMF destruction inventory and coordinates process.
• QA: Reviews and approves destruction documentation, audits vendors.
• IT: Oversees secure deletion of electronic TMF and validates erasure methods.
• Vendor: Performs physical destruction and provides Certificate of Destruction.
• Witness: Ensures destruction occurs as per SOP and documents observation.

Accountability

The sponsor is accountable for ensuring TMF destruction is compliant with FDA, EMA, CDSCO, WHO, and ICH GCP requirements. QA is accountable for oversight and record verification.

Procedure

1. Retention Verification
1.1 Verify that the retention period defined by regional regulations has lapsed.
1.2 Complete TMF Retention Verification Log (Annexure-1).
1.3 Confirm no ongoing regulatory, legal, or pharmacovigilance obligations require continued retention.

2. Preparation for Destruction
2.1 TMF Administrator prepares TMF Destruction Inventory (Annexure-2).
2.2 Secure approval from Sponsor QA before initiating destruction.
2.3 Select destruction vendor qualified and audited by QA.

3. Paper TMF Destruction
3.1 Shredding must be cross-cut or pulverization at secure facilities.
3.2 Destruction must be witnessed by authorized personnel.
3.3 Certificate of Destruction (Annexure-3) must be issued.

4. Electronic TMF Destruction
4.1 Use validated erasure methods ensuring data cannot be recovered.
4.2 Maintain IT Validation Log (Annexure-4).
4.3 For cloud storage, obtain vendor destruction confirmation.

5. Chain of Custody
5.1 Document TMF transfer from archive to destruction facility.
5.2 Maintain TMF Chain of Custody Log (Annexure-5).

6. Documentation of Destruction
6.1 Certificate of Destruction must specify date, method, documents destroyed, and witness details.
6.2 File destruction documentation in TMF Destruction File.
6.3 Retain Certificate of Destruction permanently.

7. QA Oversight
7.1 QA audits destruction records annually.
7.2 Any deviation must be reported and CAPA initiated.

Abbreviations

• SOP: Standard Operating Procedure
• TMF/eTMF: Trial Master File / electronic Trial Master File
• QA: Quality Assurance
• IT: Information Technology
• CRO: Contract Research Organization
• CAPA: Corrective and Preventive Action

Documents

1. TMF Retention Verification Log (Annexure-1)
2. TMF Destruction Inventory (Annexure-2)
3. Certificate of Destruction (Annexure-3)
4. IT Validation Log (Annexure-4)
5. TMF Chain of Custody Log (Annexure-5)

References

• ICH E6(R2/R3) – Essential Documents
• FDA – TMF Record Management
• EMA – TMF Destruction Guidance
• CDSCO – Clinical Trial Record Retention
• WHO – TMF Record Handling and Destruction

Version: 1.0

Approval Section

Annexures

Annexure-1: TMF Retention Verification Log

Annexure-2: TMF Destruction Inventory

Annexure-3: Certificate of Destruction

Annexure-4: IT Validation Log

Annexure-5: TMF Chain of Custody Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-tmf-archiving-and-retention-multi-region-rules”
},
“headline”: “SOP for TMF Archiving and Retention (Multi-Region Rules)”,
“description”: “This SOP defines standardized processes for archiving and retaining Trial Master Files (TMF/eTMF) in compliance with multi-regional requirements including FDA, EMA, CDSCO, and WHO, covering secure storage, retention timelines, access, retrieval, and inspection readiness.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for TMF Archiving and Retention (Multi-Region Rules)

Purpose

The purpose of this SOP is to establish standardized processes for archiving and retaining Trial Master Files (TMF/eTMF) in compliance with multi-regional requirements. Proper archiving ensures that essential documents are preserved, secure, accessible, and inspection-ready for the retention period defined by regulatory authorities such as FDA, EMA, CDSCO, MHRA, PMDA, and WHO.

Scope

This SOP applies to all clinical trials conducted by the sponsor or through CROs where TMF/eTMF archiving and retention obligations exist. It covers procedures for indexing, secure storage, environmental controls, access, retrieval, and compliance with country-specific retention rules.

Responsibilities

• Sponsor: Ensures TMF/eTMF is archived and retained according to regulatory requirements.
• TMF Administrator: Manages indexing, secure storage, and retrieval processes.
• QA: Audits archived TMFs for integrity, security, and accessibility.
• IT/System Administrator: Manages eTMF backup, disaster recovery, and electronic archiving compliance.
• Vendors/Archivists: Ensure external archiving facilities meet regulatory standards.

Accountability

The sponsor is accountable for ensuring TMF/eTMF archiving complies with regional rules. TMF administrators and archivists are accountable for maintaining document security and accessibility. QA ensures independent verification.

Procedure

1. TMF Finalization
1.1 Perform final reconciliation of TMF/ISF before archiving.
1.2 Complete TMF Archiving Checklist (Annexure-1).
1.3 Ensure placeholders are resolved and QC checks completed.

2. Indexing and Preparation
2.1 Assign unique archive ID to each TMF.
2.2 Prepare TMF Archive Inventory Log (Annexure-2).
2.3 For eTMF, lock database, generate audit trail, and prepare read-only archive version.

3. Archiving Facilities
3.1 Store paper TMFs in controlled facilities with temperature 18–25°C and humidity 30–60%.
3.2 Facilities must have restricted access, fire protection, and disaster recovery systems.
3.3 For eTMFs, archive in validated systems with backup at separate geographic location.

4. Access and Retrieval
4.1 Access must be restricted to authorized personnel.
4.2 Maintain Archive Access Log (Annexure-3).
4.3 Retrieval requests must be documented and justified.

5. Retention Timelines (Examples)
5.1 FDA (21 CFR 312.57): 2 years after NDA approval or discontinuation.
5.2 EMA (Directive 2005/28/EC): 25 years for essential documents.
5.3 MHRA: Minimum 25 years.
5.4 CDSCO: Minimum 15 years.
5.5 WHO: Minimum 15 years or per product-specific requirements.

6. Transfer or Migration
6.1 Document any TMF transfer between facilities or vendors.
6.2 For eTMF migration, validate system transfer and reconcile documents.
6.3 Record details in TMF Transfer Log (Annexure-4).

7. Monitoring and Audit
7.1 QA audits archived TMFs annually for security and integrity.
7.2 Archive vendors must be qualified and re-qualified every 3 years.

Abbreviations

• SOP: Standard Operating Procedure
• TMF/eTMF: Trial Master File / electronic Trial Master File
• QA: Quality Assurance
• ISF: Investigator Site File
• NDA: New Drug Application
• FDA: Food and Drug Administration
• EMA: European Medicines Agency
• MHRA: Medicines and Healthcare products Regulatory Agency
• CDSCO: Central Drugs Standard Control Organization
• WHO: World Health Organization

Documents

1. TMF Archiving Checklist (Annexure-1)
2. TMF Archive Inventory Log (Annexure-2)
3. Archive Access Log (Annexure-3)
4. TMF Transfer Log (Annexure-4)

References

• ICH E6(R2/R3) – Section 8 Essential Documents
• FDA – Record Retention Requirements
• EMA – Archiving Guidance
• CDSCO – Record Retention Requirements
• WHO – Essential Document Archiving

Version: 1.0

Approval Section

Annexures

Annexure-1: TMF Archiving Checklist

Annexure-2: TMF Archive Inventory Log

Annexure-3: Archive Access Log

Annexure-4: TMF Transfer Log

Revision History

For more SOPs visit: Pharma SOP